Helomics knows that chemotherapy isn't "one size fits all." That's why the company developed and markets ChemoFx, a product that examines the response of a specific patient's tumor to various chemotherapies. Physicians can use the test to collect cells from a solid tumor, then Helomics performs tissue cultures and tries various chemotherapeutic and biologic agents to measure the best type, combination, and dose of chemotherapy to help combat the disease in individual patients. The company has been studying ChemoFx use with ovarian and breast tumors, among others. The company markets its products and services through a direct sales force. Helomics is a subsidiary of Precision Therapeutics.
Get in Touch with 3 Contacts
Nicholas ReitzeDirector, Laboratory Operations
Bruce RobinSenior Director of Program Management
Mary ScullionInfrastructure Systems Manager